ANAB – anaptysbio, inc. (US:NASDAQ)
Stock Stats
News
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at Guggenheim.
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at JPMorgan Chase & Co. from $36.00 to $42.00. They now have an "overweight" rating on the stock.
AnaptysBio, Inc. (NASDAQ: ANAB) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
AnaptysBio GAAP EPS of -$0.72 beats by $0.91, revenue of $43.11M [Seeking Alpha]
Anaptys Announces Participation in March Investor Conferences
Form SCHEDULE 13G ANAPTYSBIO, INC Filed by: First Light Asset Management, LLC
Form 10-K ANAPTYSBIO, INC For: Dec 31
Form 8-K ANAPTYSBIO, INC For: Feb 27
Form 8-K ANAPTYSBIO, INC For: Feb 19
Form SCHEDULE 13G ANAPTYSBIO, INC Filed by: Point72 Asset Management, L.P.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.